Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Debt (2020 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Non-Current Debt for 8 consecutive years, with $61.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 4.07% year-over-year to $61.9 million, compared with a TTM value of $61.9 million through Dec 2025, up 4.07%, and an annual FY2025 reading of $61.9 million, up 4.07% over the prior year.
  • Non-Current Debt was $61.9 million for Q4 2025 at Zevra Therapeutics, up from $61.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $61.9 million in Q4 2025 and bottomed at $98000.0 in Q1 2021.
  • Average Non-Current Debt over 5 years is $34.7 million, with a median of $37.9 million recorded in 2024.
  • The sharpest move saw Non-Current Debt plummeted 60.42% in 2023, then soared 1074.58% in 2024.
  • Year by year, Non-Current Debt stood at $98000.0 in 2021, then skyrocketed by 12961.22% to $12.8 million in 2022, then tumbled by 60.42% to $5.1 million in 2023, then skyrocketed by 1074.58% to $59.5 million in 2024, then grew by 4.07% to $61.9 million in 2025.
  • Business Quant data shows Non-Current Debt for ZVRA at $61.9 million in Q4 2025, $61.3 million in Q3 2025, and $60.7 million in Q2 2025.